evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

6 questions · 10 findings · 4 reviews · Dental caries · All outcomes

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 1 · 10%GRADE not reported 7 · 70%Very low 0 · 0%Low 1 · 10%Moderate 0 · 0%High 1 · 10%

Any of the interventions (CR, SE, SW, sealing with sealant materials, Hall Technique, or NRCC) vs Each other, placebo, or no treatment

Adverse events (any type) and safety of sealant · Children and/or adults with permanent or primary teeth, vital (sensitive) pulps, and cavitated or dentine carious lesions conventionally…

The review found no eligible studies for this question.

1 finding from 1 review

Resin-based fissure sealant vs Fluoride varnish

Safety of sealants and fluoride varnishes (adverse events) · Children and adolescents (general population, aged under 20 years)
1 finding from 1 review

Silver diamine fluoride (SDF) vs Not applicable (single-arm safety outcome)

Serious adverse events · Children and older adults treated with SDF for carious lesions

No serious adverse events (e.g., allergic reactions or toxicity) were reported for SDF across the reviews (ungraded).

1 finding from 1 review

Silver diamine fluoride (SDF) vs Not applicable (single-arm safety outcome)

Adverse events: black staining of arrested lesions · Children and older adults treated with SDF for carious lesions

Black staining of arrested lesions was the main adverse event of SDF (reported by seven reviews); it was generally acceptable to patients (ungraded).

1 finding from 1 review

Intraglandular botulinum neurotoxin (BoNT) injection vs placebo injection

Reduction in frequency and severity of drooling · Adults with Parkinson's disease and sialorrhea (drooling)

Type A botulinum toxin significantly reduced DSFS scores versus placebo (SMD -0.80, 95% CI -1.25 to -0.36; ungraded subgroup).

3 findings from 1 review

Intraglandular botulinum neurotoxin (BoNT) injection vs placebo injection

Adverse events (participants with >=1 adverse event) · Adults with Parkinson's disease and sialorrhea (drooling)

Type A botulinum toxin showed a borderline, non-significant increase in adverse events versus placebo (RD 0.10, 95% CI 0.00 to 0.21; ungraded subgroup).

3 findings from 1 review